在英国未接种卡介苗成人中比较雾化吸入减毒牛分枝杆菌卡介苗与皮内卡介苗结核控制性人类感染模型安全性的剂量递增随机对照1期试验
这项1期控制性人类感染试验在英国两个临床研究中心开展,纳入未感染结核分枝杆菌且未接种卡介苗的健康成人,经剂量递增选定雾化吸入卡介苗最大耐受剂量后随机比较雾化吸入与皮内接种的安全性。结果显示雾化组与皮内组不良事件频率无显著差异,但雾化组严重全身不良事件更多,所有雾化后不良事件均自行缓解。
要点
- 雾化吸入减毒牛分枝杆菌卡介苗最高至1×10^7 CFU耐受性良好。
- 雾化组与皮内组全身及呼吸系统不良事件频率无显著差异。
- 雾化组严重全身不良事件比例高于皮内组,所有事件自行缓解。
核心结论
- 首次人体雾化吸入卡介苗控制性人类感染模型耐受性良好,进一步工作将评估该模型在疫苗效力评价和识别保护相关因素方面的效用。
研究设计与样本
- 1期控制性人类感染试验,在英国两个临床研究机构开展,纳入18-50岁未感染结核分枝杆菌且未接种卡介苗、无哮喘或其他呼吸系统疾病史的健康免疫正常成人。
- 参与者先入组1组(卡介苗丹麦株),因全球丹麦株短缺暂停并修改方案后以卡介苗保加利亚株重启为2组;剂量递增阶段依次给予1×10^3、1×10^4、1×10^5、1×10^6或1×10^7 CFU雾化卡介苗以选定最大耐受剂量。
- 随机对照试验按9:12比例采用可变区组随机化和顺序编号密封信封,将参与者分配至雾化卡介苗(1×10^7 CFU)加皮内生理盐水组或皮内卡介苗(1×10^6 CFU)加雾化生理盐水组,参与者对治疗分配设盲至第14天。
- 主要结局为比较基于雾化吸入卡介苗与基于皮内接种卡介苗的控制性人类感染模型的安全性,次要结局为评估雾化组气道和皮内组皮肤活检中卡介苗的回收,采用培养和PCR检测卡介苗。
- 试验注册于ClinicalTrials.gov,NCT02709278,已完成。
主要发现
- 2016年4月7日至2018年9月29日评估资格;1组筛查15人,入组13人,10人完成研究;2组筛查60人,入组33人,全部完成研究。
- 雾化吸入卡介苗剂量至1×10^7 CFU耐受性良好;雾化组与皮内组不良事件频率无显著差异:每人诱发不良事件中位百分比,雾化后 vs 皮内卡介苗后,全身7%[IQR 2-11] vs 4%[1-13],p=0.62;呼吸系统7%[1-19] vs 4%[1-9],p=0.56。
- 雾化卡介苗后2周内严重全身不良事件多于皮内卡介苗后:15/122(12%) vs 1/94(1%),差值11%[95%CI 5-17],p=0.0013;呼吸系统不良事件严重程度无差异:2/144(1%) vs 0/97(0%),差值1%[-1至3],p=0.52。
- 雾化卡介苗后所有不良事件均自行缓解;报告1例严重不良事件,为2组一名参与者因既存卵巢囊肿入院接受镇痛治疗,判定与卡介苗感染无关。
- 第14天,雾化感染后支气管肺泡灌洗液样本和皮内感染后皮肤活检样本均培养出卡介苗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mycobacterium tuberculosis is the main causative agent of tuberculosis. BCG, the only licensed vaccine, provides inadequate protection against pulmonary tuberculosis. Controlled human infection models are useful tools for vaccine development. We aimed to determine a safe dose of aerosol-inhaled live-attenuated Mycobacterium bovis BCG as a surrogate for M tuberculosis infection, then compare the safety and tolerability of infection models established using aerosol-inhaled and intradermally administered BCG. METHODS: This phase 1 controlled human infection trial was conducted at two clinical research facilities in the UK. Healthy, immunocompetent adults aged 18-50 years, who were both M tuberculosis-naive and BCG-naive and had no history of asthma or other respiratory diseases, were eligible for the trial. Participants were initially enrolled into group 1 (receiving the BCG Danish strain); the trial was subsequently paused because of a worldwide shortage of BCG Danish and, after protocol amendment, was restarted using the BCG Bulgaria strain (group 2). After a dose-escalation study, during which participants were sequentially allocated to receive either 1 × 103, 1 × 104, 1 × 105, 1 × 106, or 1 × 107 colony-forming units (CFU) of aerosol BCG, the maximum tolerated dose was selected for the randomised controlled trial. Participants in this trial were randomly assigned (9:12), by variable block randomisation and using sequentially numbered sealed envelopes, to receive aerosol BCG (1 × 107 CFU) and intradermal saline or intradermal BCG (1 × 106 CFU) and aerosol saline. Participants were masked to treatment allocation until day 14. The primary outcome was to compare the safety of a controlled human infection model based on aerosol-inhaled BCG versus one based on intradermally administered BCG, and the secondary outcome was to evaluate BCG recovery in the airways of participants who received aerosol BCG or skin biopsies of participants who received intradermal BCG. BCG was detected by culture and by PCR. The trial is registered at ClinicalTrials.gov, NCT02709278, and is complete. FINDINGS: Participants were assessed for eligibility between April 7, 2016, and Sept 29, 2018. For group 1, 15 participants were screened, of whom 13 were enrolled and ten completed the study; for group 2, 60 were screened and 33 enrolled, all of whom completed the study. Doses up to 1 × 107 CFU aerosol-inhaled BCG were sufficiently well tolerated. No significant difference was observed in the frequency of adverse events between aerosol and intradermal groups (median percentage of solicited adverse events per participant, post-aerosol vs post-intradermal BCG: systemic 7% [IQR 2-11] vs 4% [1-13], p=0·62; respiratory 7% [1-19] vs 4% [1-9], p=0·56). More severe systemic adverse events occurred in the 2 weeks after aerosol BCG (15 [12%] of 122 reported systemic adverse events) than after intradermal BCG (one [1%] of 94; difference 11% [95% CI 5-17]; p=0·0013), but no difference was observed in the severity of respiratory adverse events (two [1%] of 144 vs zero [0%] of 97; 1% [-1 to 3]; p=0·52). All adverse events after aerosol BCG resolved spontaneously. One serious adverse event was reported-a participant in group 2 was admitted to hospital to receive analgesia for a pre-existing ovarian cyst, which was deemed unrelated to BCG infection. On day 14, BCG was cultured from bronchoalveolar lavage samples after aerosol infection and from skin biopsy samples after intradermal infection. INTERPRETATION: This first-in-human aerosol BCG controlled human infection model was sufficiently well tolerated. Further work will evaluate the utility of this model in assessing vaccine efficacy and identifying potential correlates of protection. FUNDING: Bill & Melinda Gates Foundation, Wellcome Trust, National Institute for Health Research Oxford Biomedical Research Centre, Thames Valley Clinical Research Network, and TBVAC2020.
引用
- Satti I, Marshall JL, Harris SA, et al. Safety of a controlled human infection model of tuberculosis with aerosolised, live-attenuated Mycobacterium bovis BCG versus intradermal BCG in BCG-naive adults in the UK: a dose-escalation, randomised, controlled, phase 1 trial. Lancet Infect Dis. 2024. PMID: 38621405. doi:10.1016/S1473-3099(24)00143-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。